In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs Guidance for Industry
工業指南中ANDAs申請遞交的外用提交的外用制劑的體外釋放試驗研究

INTRODUCTION 緒論

This guidance is intended to assist applicants who are submitting abbreviated new drug applications (ANDAs) for liquid-based and/or other semisolid products applied to the skin, including integumentary and mucosal (e.g., vaginal) membranes, which are hereinafter called topical products. Because of the complex route of delivery associated with these products, which are typically locally acting, and the potential complexity of certain formulations, topical products (other than topical solutions) are classified as complex products. This guidance provides recommendations for in vitro release test (IVRT) studies that can be used to compare a proposed generic (test) topical product and its reference standard (RS) for the purpose of supporting a demonstration of bioequivalence (BE) to the reference listed drug (RLD). The reference standard ordinarily is the RLD.4

本指南旨在幫助申請人提交適用于皮膚的液體和/或其他半固體產品的仿制藥申請（ANDA），包括皮膚和粘膜（如陰道），以下稱為局部產品。由于與這些產品相關的復雜遞送途徑（通常是局部作用的）以及某些制劑的潛在復雜性，局部產品（非局部溶液）被歸類為復雜產品。本指南為體外釋放試驗（IVRT）研究提供了建議，該研究可用于比較擬用非**（試驗）局部產品及其參考標準品（RS），以支持證明與參考上市藥物（RLD）的生物等效性（BE）。參考標準通常為RLD。

This guidance does not address drug products that are administered via ophthalmic, otic, nasal, inhalation, oral, or injection-based routes, or that are transdermal or topical delivery systems (including products known as patches, topical patches, or extended-release films).

本指南不適用于通過眼、耳、鼻、吸入、口服或注射途徑給藥的藥物產品，也不適用于經皮或局部給藥系統（包括貼片、局部貼片或緩釋膜產品）。

It is beyond the scope of this guidance to discuss specific topical products to which this guidance applies. FDA recommends that applicants consult this guidance and any relevant productspecific guidances (PSGs) and any other relevant guidances for industry, when considering the design and conduct of IVRT studies that, in conjunction with other studies, as deemed necessary, may be appropriate to support a demonstration that a proposed generic topical product and its RLD are bioequivalent. FDA also recommends that applicants routinely refer to FDA’s guidance web pages, because additional guidances may become available that could assist in the development of a generic topical product.

討論本指南適用的特定主題產品超出了本指南的范圍。FDA建議申請人在考慮IVRT研究的設計和實施時，參考本指南和任何相關的產品特定指南（PSG）以及任何其他相關的行業指南，這些研究與其他研究（如有必要）可能適用于證明擬用仿制藥及其RLD具有生物等效性。FDA還建議申請人定期參考FDA的指導網頁，因為可能會有其他指導信息，有助于開發通用的外用產品。

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.

一般而言，FDA指南性文件并非具有強制執行的法律職能。實際上，指南描述了管里部門對某一問題當前的思考，并且僅作為建議，除非引用了具體的法規或法定要求，。在指南中使用“應該"一詞，意味著建議或推薦，并非要求的意思。

BACKGROUND 背景

This guidance has been developed as part of FDA’s “Drug Competition Action Plan," which, in coordination with the Generic Drug User Fee Amendments (GDUFA) program and other FDA activities, is intended to increase competition in the marketplace for prescription drugs, facilitate the entry of high-quality and affordable generic drugs, and improve public health.

本指南是作為FDA“藥品競爭行動計劃"的一部分，該計劃配合通用藥品用戶費用修正案（GDUFA）計劃和其他FDA舉措，旨在促進處方藥市場的競爭，促進高質量和實惠的藥品的進入市場，并改善公眾醫療。

The Federal Food, Drug, and Cosmetic Act (FD&C Act) generally requires an ANDA to contain, among other things, information to show that the proposed generic drug product (1) is the same as the RLD with respect to the active ingredient(s), conditions of use, route of administration, dosage form, strength, and labeling (with certain permissible differences); and (2) is bioequivalent to the RLD. Thus, an ANDA will not be approved if the information submitted in the ANDA is insufficient to show that the test product is bioequivalent to the RLD.

《聯邦食品、藥品和化妝品法案》（FD&C法案）通常要求ANDA包含合適的信息，說明：仿制藥與RLD相比（1）具有相同的活性成分、使用條件、給藥途徑、劑型、規格和標簽方面（允許存在某些的差異）；和（2）與RLD生物等效。因此，如果ANDA中提交的信息不足以證明自制制劑與RLD具有生物等效性，ANDA將不予批準。

An IVRT study may be used to assess the rate of drug release (i.e., release of an active ingredient) from a topical product. Once validated, an IVRT study may also be useful in controlling product quality and/or establishing the acceptability of post-approval manufacturing changes. This guidance focuses on general considerations and recommendations for the method 66 development, method validation, and conduct of IVRT studies that are submitted in ANDAs and intended to support a demonstration of BE.

IVRT研究可用于評估局部產品的藥物釋放速率（即活性成分的釋放）。一旦驗證，IVRT研究也可用于控制產品質量和/或確定批準后制造變更的可接受性。本指南側重于方法開發、方法驗證和IVRT研究的一般考慮和建議，這些研究在ANDA申請中提交，旨在支持BE的論證。

IVRT METHOD DEVELOPMENT IVRT 方法開發

If an IVRT study is intended to support a demonstration of BE, the IVRT method development report should be submitted in the ANDA to show how the IVRT method was optimized, and to support a demonstration that the method parameters selected for the IVRT are appropriate or necessary, particularly in situations where the method parameters are different from the methods recommended in this guidance and described in the United States Pharmacopeia (USP) General Chapter . The Agency’s interest in reviewing the method development report is to understand why specific IVRT method parameters were selected and whether they are suitably sensitive and reproducible. This method development report should clearly indicate/distinguish the method parameters used for each set of data, illustrate the efforts made to optimize the IVRT method, and demonstrate that the method parameters selected for the IVRT are appropriate.

如果IVRT研究旨在支持BE的論證，則應在ANDA中提交IVRT方法開發報告，以顯示IVRT方法是如何優化的，并支持為IVRT選擇的方法參數是合適或必要的演示，特別是在方法參數不同于本指南中推薦的方法和美國藥典（USP）一般章節中描述的方法的情況下。監管機構在審查方法開發報告時，比較關注IVRT方法參數選擇的合理性，以及這些參數是否具有合適的敏感度和重現性。該方法開發報告應明確指出/區分每組數據所用的方法參數，說明為優化IVRT方法所做的努力，并證明為IVRT選擇的方法參數是合適的。

Applicants are encouraged to use the recommendations in this guidance, and if an applicant elects to use methods that are different from those recommended in this guidance, the IVRT method development report should demonstrate why it is scientifically justified to use an alternative approach than what is recommended in this guidance or USP to optimize the IVRT method. Specific examples of procedures are described in subsequent sections, to help applicants identify circumstances when information should be submitted in the ANDA to explain why an alternative procedure was utilized.

鼓勵申請人使用本指南中的建議，如果申請人選擇使用與本指南中建議的方法不同的方法，IVRT方法開發報告應說明選擇替代方法，進行IVRT方法優化的科學合理性。后續章節中描述了具體示例，以幫助申請人確定應在ANDA中提交信息的情況，以解釋為什么使用替代的方法。

The IVRT method development studies, being exploratory in nature, are often performed using a sample analytical method that is not validated (e.g., a high-performance liquid chromatography (HPLC) or ultrahigh performance liquid chromatography (UPLC) method); also, IVRT method development studies are often conducted in a manner that is not compatible with a quality management system which would otherwise make the evidence generated suitable to support valid conclusions. Such method development studies would not be suitable to demonstrate the validity of an IVRT method, or the associated results. Therefore, although it may appear to be redundant, certain experiments performed during IVRT method development may need to be repeated during IVRT method validation, using appropriate controls, like a validated analytical method and procedures that are compatible with a suitable quality management system.

IVRT方法開發研究本質上是探索性的，通常使用未經驗證的樣品分析方法（例如，高效液相色譜（HPLC）或超高效液相色譜儀（UPLC）方法）進行；此外，IVRT方法開發研究通常以與質量管理體系不兼容的方式進行，所生成的證據不足以支持結論的可靠性。此類方法開發研究不適于證明IVRT方法或相關結果的有效性。因此，盡管這可能顯得多余，但在IVRT方法驗證期間，可能需要使用適當的控制措施（如與適當的質量管理體系兼容的經驗證的分析方法和程序）重復IVRT方法開發期間進行的某些實驗。

It is important to clearly segregate and consistently identify those experiments and results that were part of IVRT method development separately from those that were part of IVRT method validation. It is also important to consistently identify all relevant method parameters and experimental conditions/controls for each set of IVRT results. Information in the method development report should clearly identify/distinguish when the results for apparently similar sets of experiments may have been obtained using different method parameters. Method development reports should clarify which sets of diffusion cells were run in parallel or separately (e.g., on separate days). In addition, the sample analytical method (e.g., a HPLC or UPLC method) used to analyze the samples from each set of IVRT experiments should be specified, and the reports should indicate whether or not the sample analytical method was validated (either at the time of sample analysis or subsequently).

將IVRT方法開發過程中的實驗和結果與IVRT方法驗證過程中的試驗和結果分開進行明確區分和一致識別是非常重要的。對于每組IVRT結果，一致地確定所有相關的方法參數和實驗條件/對照也很重要。方法開發報告中的信息應明確識別/區分使用不同方法參數可能獲得的明顯相似實驗組的結果。方法的開發報告應澄清平行或單獨運行的擴散池組（例如，在不同的日期）。此外，應確定用于分析每組IVRT實驗樣本的樣品分析方法（例如HPLC或UPLC方法），報告應說明樣品分析方法是否有經過驗證（在樣品分析時或隨后）。

A. IVRT Method Parameters IVRT 方法參數

Theoretical or empirical information should be provided to explain the selection of IVRT method parameters such as the equipment, product dose amount, sampling times, stirring/agitation rate, etc. When the equipment selected is among the models of equipment in the USP<1724>, Semisolid Drug Products – Performance Tests, and when the product dose amount or stirring rate is a parameter that is fixed (not adjustable) with the selected equipment, it may be sufficient to explain these facts.

應提供理論或經驗信息，以解釋IVRT方法參數的選擇，如設備、上樣量、取樣時間、攪拌/攪拌速率等。當選擇的設備是USP<1724>半固體藥物制劑—性能測試中所述設備時，且上樣量或攪拌速率與所選的設備匹配（未調節），可充分解釋選擇的合理性。

It is unconventional for IVRT sampling times to be selected within a study duration of less than 4 hours. This may occur in situations where the fixed product dose was depleted to such a great extent by 4 hours that the release kinetics were no longer linear thereafter (when plotted vs. the square root of time). In such instances, it would be appropriate to explain the efforts that were made to optimize the IVRT method (e.g., using a different diffusion cell equipment that allowed for a larger product dose to be used) so that the sustained steady state release kinetics could potentially be characterized over a conventional IVRT duration of 4 to 6 hours.

通常情況下，IVRT取樣時長不應少于4小時。但是，對于某些特定類型的制劑，這可能發生在固定產品劑量在4小時內耗盡到如此大的程度，以至于釋放動力學此后不再是線性的情況下（當以釋放量對時間的平方根作圖）。在這種情況下，應解釋為優化IVRT方法所做的努力（例如，使用允許使用更大產品上樣量的不同擴散池設備），以便在4至6小時的常規IVRT持續時間內可能表征持續的穩態釋放動力學。

B. IVRT Receptor Solution  IVRT接收介質

It is conventional to evaluate different receptor solutions during IVRT method development (all using the same membrane that has broad chemical compatibility with the receptor solutions evaluated); these receptor solutions are frequently binary hydro-alcoholic mixtures selected based upon the solubility and stability of the (frequently hydrophobic) drug in the receptor solution. The receptor solutions are conventionally sampled at least hourly across a 6-hour duration.

通常，需要在IVRT方法開發過程中對不同接受介質進行評估都使用與待評估的接受介質具有廣泛化學相容性的同一類型膜）；這些接受液通常是基于受體溶液中（通常是疏水性的）藥物的溶解度和穩定性而選擇的二元水醇混合物。接受液通常在6小時持續時間內至少每小時取樣一次。

???

Information on the empirical solubility and stability of the drug in the receptor solution, as well as information on the linearity and precision of the resulting drug release rate in an IVRT should be provided to help explain the selection of a receptor solution for the test method. The linearity of the drug release rate (slope) across all time points should ideally have an r2 value of ≥ 0.97. In situations where the solubility of the drug in the receptor solution limits the release kinetics, causing a reduction in the release rate at the last time point(s), it may be appropriate to evaluate different receptor solutions. It may be appropriate to truncate the IVRT method to a 4- or 5-hour sampling duration if the linearity of the release rate in that truncated duration is improved (exhibiting a higher r2 value), and if other aspects of the release kinetics (e.g., precision) in that receptor solution are optimized compared to other receptor solutions evaluated.

應提供藥物在接受液中的經驗溶解度和穩定性的信息，以及IVRT中產生的藥物釋放率的線性和精密度的信息，用于解釋試驗方法中接受液選擇的合理性。理想情況下，所有時間點的藥物釋放速率（斜率）應成線性關系（r2值≥ 0.97）.如何在藥物在接受液中的溶解度限制釋放動力學，導致最后一個時間點釋放速率降低的情況下，評估不同的接受液可能是更有必要的。如果縮短的時間段內釋放速率的線性得到改善（表現出較高的r2值），并且與評估的其他受體溶液相比，該受體溶液中釋放動力學的其他方面（例如，精度）得到優化，則將IVRT方法縮短為4小時或5小時的采樣時間段可能是合適的。

One advantage of selecting an optimal receptor solution as an initial step in IVRT method development is that it allows for the sample analysis method to be optimized for the selected receptor solution sample matrix before proceeding to an evaluation of different membranes using that receptor solution.

選擇最佳受體溶液作為IVRT方法開發的初始步驟的一個優點是，在使用接受液對不同膜進行評估之前，可先選定的接受液對樣品分析方法進行優化。

C. IVRT Membrane IVRT膜

It is conventional to evaluate different membranes during IVRT method development (all using the same receptor solution); these membranes are frequently synthetic membranes used for the filtration of particulate matter in solutions. IVRT membranes are selected based upon their effective pore size (e.g., 0.45 micrometers (µm)), as well as their expected inertness to binding the drug. Information should be provided in the IVRT method development report on each membrane’s binding to the drug and its chemical compatibility with relevant receptor solution(s) selected for the IVRT method (based on the preceding phase of IVRT method development), as well as information on the linearity and precision of the resulting release rate when each membrane is used in an IVRT, as this information can help to explain why a specific membrane is optimal for the IVRT method.

在IVRT方法開發過程中，通常評估不同的膜（均使用相同的接受液）；這些膜通常是用于過濾溶液中的顆粒物質的合成膜。IVRT膜的選擇基于其有效孔徑（例如0.45微米（µm））以及其與藥物結合的預期惰性。IVRT方法開發報告中應提供每種膜與藥物的結合及其與為IVRT方法選擇的相關受體溶液的化學相容性的信息（基于IVRT方法發展的前一階段），以及在IVRT中使用每種膜時所產生的釋放速率的線性和精度的信息，因為該信息可以幫助解釋為什么特定膜對于IVRT方法是最佳的。

IV. IVRT METHOD VALIDATION IVRT  方法驗證

The equipment, methodologies, and study conditions used in the IVRT pivotal study should be appropriately validated or qualified. It is conventional to initiate the validation of the sample analytical method (e.g., a HPLC or UPLC method) for the IVRT before initiating the IVRT method validation itself, although certain components of the sample analysis method validation (e.g., stability) often proceed in parallel with the IVRT method validation. If an applicant elects to use equipment, methodologies, or study conditions that are different from those recommended in this guidance or in USP , the applicant should demonstrate why the differences are scientifically justified. It is important to consistently identify all relevant method parameters for each set of IVRT results, making it clear that the results were obtained using the same IVRT method parameters, and clarifying which sets of diffusion cells were run in parallel or separately. Detailed protocols and well-controlled test procedures are recommended to ensure the precise control of dosing, sampling, and other IVRT study parameters, and of potential sources of experimental bias.

IVRT關鍵研究中使用的設備、方法和研究條件應經過合理的驗證或確認。在啟動IVRT方法驗證之前，啟動IVRT的樣品分析方法（例如，HPLC或UPLC方法）的驗證是常規的，盡管樣品分析方法驗證的某些試驗（例如，穩定性）通常與IVRT方法的驗證平行進行。如果申請人選擇使用的設備、方法或研究條件與本指南或USP中推薦的不同，申請人應證明這些差異在科學上是合理的。重要的是要一致地確定每組IVRT結果的所有相關方法參數，明確結果是使用相同的IVRT方法參數獲得的，并闡明哪些組擴散池是平行或單獨運行的。建議建立詳細的方案和嚴格控制的測試程序，以確保精確控制上樣、取樣和其他IVRT研究參數，以及實驗偏差的潛在來源。

The qualification of an IVRT method parameter refers to the process of defining what attributes make it suitable to perform its function in the IVRT method. For example, when hourly measurements of the temperature at the membrane surface (when mounted in a diffusion cell) demonstrate that an IVRT equipment can maintain a membrane surface temperature in the range of 32°C ± 1°C across 6 hours, the results can support a demonstration that the equipment is qualified to perform its function in an IVRT method for which a method parameter is the control of membrane surface temperature in the range of 32°C ± 1°C across 6 hours. While an IVRT membrane surface temperature in the range of range of 32°C ± 1°C is appropriate for topical products applied on the skin, for topical products applied on mucosal membranes (e.g., a vaginal gel) the relevant IVRT membrane surface temperature would be 37°C ± 1°C. The validation of the IVRT method should incorporate the following qualifications and controls, performed using validated sample analytical procedures, as applicable.

IVRT方法參數的限定指的是定義哪些屬性適合在IVRT方法中執行其功能的過程。例如，當每小時測量膜表面溫度（當安裝在擴散池中時）表明IVRT設備可以在6小時內將膜表面溫度保持在32°C±1°C的范圍內時，結果可以證明該設備在IVRT方法中執行其功能，其中方法參數是在6小時內將膜表面溫度控制在32°C±1°C的范圍內。盡管IVRT膜表面溫度在32°C±1°C范圍內適用于涂抹在皮膚上的局部產品，但對于粘膜外用制劑（如陰道凝膠），相關IVRT膜的表面溫度應為37°C±1°C。如適用，使用經驗證的樣品分析方法，在IVRT方法的驗證進行以下確認和控制。

A. Equipment Qualification設備確認

Suitable equipment for the IVRT method are described in USP General Chapter . These include different models of a vertical diffusion cell and an immersion cell. Other models of vertical diffusion cells and immersion cells that are essentially the same in design and/or operational principles as those described in USP General Chapter may also be suitable.

在USP<1724>通用章節中有適用于IVRT方法的設備描述。（淺析FDA指導原則中對申報用Franz測試裝置的要求）這些包括不同模型的垂直擴散池和浸沒池的。在設計和/或操作原理上與USP<1724>通用章節中描述的那些基本相同的垂直擴散池和浸沒池的其他模型也可能使用。

The operating principles and specific test procedures differ among the various equipment; relevant procedures from the manufacturer may be used for installation, operation, and performance qualifications. The laboratory qualification of each diffusion cell should, at minimum, include: (1) measurements of the diffusional area of the orifices of the donor and receptor compartments between which the membrane is mounte; (2) the empirically measured volume of the receptor solution compartment/vessel for each diffusion cell; (3) the stability of the temperature measured at the membrane surface (e.g., at 32°C ± 1°C), or just below the membrane, across a relevant duration (e.g., 6 hours); and (4) the rate of stirring or agitation, as applicable.

每種設備的工作原理和特定測試方法不同；制造商的相關程序可用于安裝、操作和性能鑒定。每個擴散池的實驗室確定，至少應包括：（1）測量供給室和接受室之間膜安裝位置的孔口的擴散面積，；（2） 每個擴散池的接受室的容積；（3）在相關研究持續時間（例如，6小時）內測量膜表面（例如，32°C±1°C）或膜正下方的溫度，的穩定性；以及（4）如適用，測定攪拌或攪拌的速率。

If information related to the diffusional area of the orifice and the volume of the receptor solution compartment for each diffusion cell is available from the manufacturer, that information should be provided for each relevant diffusion cell, in addition to the empirical measurements made by the laboratory. The equipment should control the diffusion cell thermoregulation so that the membrane surface temperature is verified to be stable (e.g., at 32°C ± 1°C) for each diffusion cell (e.g., measured by a calibrated infrared thermometer) before dosing. If it is not feasible to verify that the membrane surface temperature of a diffusion cell has equilibrated and stabilized (e.g., at 32°C ± 1°C) before dosing because of design and operating principles of a specific equipment, the qualification of that equipment should demonstrate that, under the specific conditions used for the IVRT method, the membrane surface temperature can be expected to be stable (e.g., at 32°C ± 1°C) for each diffusion cell throughout the test.

如果制造商提供了與每個擴散池的孔擴散面積和接受室容積相關的信息，則除了實驗室進行的經驗測量外，還應提供每個相關擴散池的信息。設備應控制擴散池溫度調節，以便在給藥前驗證每個擴散池的膜表面溫度是否穩定（例如，32°C±1°C）（例如，通過校準的紅外溫度計測量）。如果由于特定設備的設計和操作原理，在給藥前無法驗證擴散池的膜表面溫度是否已達到平衡和穩定（例如，在32°C±1°C），對于該類型的設備確認應證明，在IVRT方法使用的特定條件下，在整個測試過程中，每個擴散池的膜表面溫度可以預期保持穩定的（例如，在32°C±1°C）。（如下圖，膜溫度平衡預實驗）

B. Membrane Qualification  膜確認

Membrane inertness should be evaluated in relation to membrane binding of the drug in the receptor solution at a concentration relevant to the range of drug concentrations in the receptor solution during the test. Determinations should be based upon a minimum of three replicate membrane incubations for the IVRT duration at the relevant temperature (e.g., 6 hours at 32°C ± 1°C). Three replicate control incubations should be performed in parallel, without membranes, to monitor for drug loss that is not associated with membrane binding. Aliquots of these solutions should be collected before and after the duration of incubation, to assess any decrease in the amount of drug in solution. The recovery of drug in solution is recommended to be within the range of 100% ± 5% at the end of the test duration to qualify the inertness of the membrane.

在試驗期間，應在與接受液中藥物濃度范圍下，根據藥物在接受液中與膜吸附來評估膜惰性。測定應基于在相關溫度下（例如，32°C±1°C下6小時）IVRT持續時間內至少重復三次膜孵育。應在沒有膜的情況下平行進行三次重復對照孵育，以監測與膜結合無關的藥物損失。應在孵育前后收集這些溶液的等分試樣，以評估溶液中藥物量的減少。建議在試驗結束時，溶液中藥物的回收率在100%±5%的范圍內，可以確認膜的惰性。

C. Receptor Solution Qualification  接收介質確認

The reason for selecting the composition of the receptor solution used for the IVRT study should be explained. The solubility of the drug in the IVRT receptor solution should be empirically determined in triplicate, to illustrate that the solubility of the drug in the receptor solution exceeds the highest sample concentration in the IVRT pivotal study, ideally by an order of magnitude, but demonstrably sufficient to facilitate a linear (steady state) release rate for the duration of the study (even when evaluating the relatively higher release rate of a formulation that is 150% of the nominal strength of the RS during the IVRT method validation)

應解釋選擇IVRT研究所用接受液成分的原因。藥物在IVRT接受液中的溶解度，應根據經驗測定一式三份，以說明藥物在接受液中溶解度超過IVRT正式研究中的最大藥物濃度，理想情況下是一個數量級或者是足以促成研究期間釋放速率的線性關系（穩態）（即使在IVRT方法驗證期間評估配方的相對較高釋放率時，即RS標稱規格的150%）

D. Receptor Solution Sampling Qualification  接收液取樣確認

The accuracy and precision of receptor solution sample collection at each time point should be appropriately qualified. Evidence to qualify a sampling procedure should illustrate that the sampling technique can reliably collect a consistent volume of the sample from the well-mixed volume of the receptor compartment at each sampling event, and that no artifacts are likely to be created by the sampling technique (e.g., because of carryover between samples in automated sampling systems or because of sampling from an unmixed volume in the sampling arm of a vertical diffusion cell). Information should be included describing the equipment manufacturer’s specification for the accuracy and precision of receptor solution sampling, when available.

每個時間點的接受液取樣的準確度和精密度應進行確認。確認取樣程序的過程應証明，取樣技術可在每次取樣時從的混合良好的接受室中可靠地收集相同體積的樣品，并且不會因取樣技術的原因引起誤差（例如，由于自動取樣系統中的樣本之間的干擾或殘留，或由于從垂直擴散池的未混合均一取樣臂中取樣）。應描述設備制造商關于接受液取樣準確度和精密度的規范信息（如有）。

E. Environmental Control  環境控制

Ambient laboratory temperature and humidity during the study should be monitored and reported. An environmentally controlled temperature range of 21°C ± 2°C is recommended, and, if feasible, a humidity range of 50% ± 20% relative humidity is recommended.

應監測和報告研究期間的實驗室環境溫度和濕度。建議環境控制溫度范圍為21°C±2°C，如果可行，建議濕度范圍為50%±20%相對濕度。

F. Linearity and Range  線性和范圍

The linearity (r2 value) of the release rate (slope) should be plotted across the range of the sampling times, which corresponds to the IVRT study duration. The linearity of drug release should be calculated and reported for each diffusion cell and compared within and across all IVRT runs. For the release rate to be considered suitably linear, it should have an r2 value ≥ 0.97 across the recommended IVRT study duration of 4–6 hours. An IVRT study duration of less than 4 hours may be insufficient to assess whether the release rates being compared for the test topical product and RS represent their steady state drug release kinetics, but an IVRT study duration of less than 4 hours (which is not recommended) may be justified if supported by compelling experimental data within the method development report to illustrate that reasonable and scientifically appropriate efforts were made to optimize the IVRT method. The IVRT method linearity and range should be established based upon the results of the precision and reproducibility runs, described further below.

在IVRT的整個研究期間，根據所有采樣時間點的釋放速率繪制標準曲線，應呈線性關系（r2值）。應計算并報告每個擴散池的藥物釋放線性方程，并與所有IVRT研究結果進行比較。為了使釋放速率為線性的前提是，建議IVRT研究持續時間為4–6小時，其應具有r2值≥0.97。通常小于4小時的IVRT研究持續時間可能不足以評估自制制劑和RS的釋放速率是否代表其穩態藥物釋放動力學，但是，如果方法開發報告中有令人信服的實驗數據支持，說明已做出合理和科學上的努力來優化IVRT方法，則IVRT研究持續時間小于4小時（不推薦）也是可以接受的。IVRT方法的線性和范圍應根據精密度和重復性試驗的結果確定，詳見如下所述。

G. Precision and Reproducibility   精密度和重現性

The intra-run and inter-run precision and reproducibility may be compared for the release rate (slopes) calculated for each diffusion cell. The mean, standard deviation, and percent coefficient of variation (%CV) among slopes may be calculated within and across all runs, and a minimum intra-run and inter-run %CV ≤ 15% is recommended. Runs may be organized to facilitate a simultaneousevaluation of intra/inter-instrumentation and/or intra/inter-operator precision and reproducibility. A minimum of three independent precision and reproducibility runs is recommended.

可以針對每個擴散池的釋放速率（斜率）計算批內和批間精密度和重現性。應計算批內和批間斜率的平均值、標準偏差和變異系數百分比（%CV），批內和批間%CV，均應≤ 15%。可以組織運行響應面實驗，以便于同時評估儀器內部/內部和/或操作員內部/內部的精密度和重復性。建議至少進行三次獨立的精密度和重現性試驗。

H. Dose Depletion   劑量消耗

The recovery of released drug in the receptor solution should be characterized in each diffusion cell as the cumulative amount of drug released into the receptor solution over the IVRT study duration. This may be expressed as a percentage of the amount of drug in the applied dose (which may be estimated based upon the nominal strength of the drug in the topical product and the approximate mass of topical product dosed on the membrane). For example, if 1 gram (g) of a topical product containing 5% drug was dosed on the membrane of each diffusion cell, the amount of drug in the applied dose may be estimated to be 50 mg. If a total of 10 mg of drug diffused into the receptor solution of each diffusion cell across the 6-hour duration of the IVRT, it would be possible to estimate that the 50 mg dose would have been depleted by 10 mg, amounting to a 20% dose depletion. The average percentage dose depletion may thereby be estimated and should be reported. While steady state release kinetics can typically be assumed under conditions when the dose depletion is less than 30%, for some topical products, steady state release kinetics may continue to be observed at higher percentage dose depletions. The IVRT method may be considered adequate despite a dose depletion of greater than 30% when experimental evidence illustrates that the release rate (slope) remains suitably linear for each diffusion cell when plotted versus the square root of time

應計算接受液中釋放藥物的回收率，用以表征IVRT研究期間，釋放到接受液中的累積藥物量。這可以表示為上樣劑量中藥物量的百分比（其可以根據外用制劑中藥物的標示規格和膜上大致上樣量來評估）。例如，如果在每個擴散池的膜上的上樣量為1克（g），制劑標示規格含有5%藥物，則上樣劑量中的藥物量可估計為50mg。如果在IVRT的6小時持續時間內，共有10mg的藥物擴散到每個擴散測試池的接受液中，則可以估計50mg劑量已經消耗10mg，相當于20%的劑量消耗。因此，可以估計并報告平均劑量消耗百分比。雖然在劑量消耗小于30%的條件下通常可以假設穩態釋放動力學，但對于一些外用制劑，在較高百分比的劑量消耗下可以繼續觀察到穩態釋放動力學。當實驗證據表明每個擴散池的釋放速率（斜率）與時間的平方根作圖時，每個擴散池的釋放速率也能保持線性關系，盡管劑量消耗大于30%，IVRT方法也被認為是考慮充分的

I.Discrimination Sensitivity, Specificity, and Selectivity   區分力—靈敏度、專屬性和選擇性

The IVRT method should be able to discriminate drug release rates from similar formulations. This should be evaluated by comparing the release rate from the test formulation with that from two comparable formulations in which the concentration of drug has been altered – one with a higher strength (150% of the nominal concentration of the RS) and one with a lower strength (50% of the nominal concentration of the RS). If precipitation of the active ingredient is observed when formulating a topical product at 150% compared to the nominal strength, it may be necessary to use different strategies, which may be discussed with the Agency before the submission of an ANDA during a pre-ANDA product development meeting or via a controlled correspondence. The composition and procedures for preparation of these higher and lower strength formulations should be reported, although these formulations need not be prepared in a manner compatible with current Good Manufacturing Practices. The discrimination ability of the IVRT method should be described using three concepts of discrimination ability: sensitivity, specificity, and selectivity.

IVRT方法應能夠區分相似制劑的藥物釋放率。應通過將試驗制劑的釋放速率與藥物濃度發生變化的兩種改變規格的制劑的釋放率進行比較來評估這一點——一個較高規格（RS標稱濃度的150%），另一個較低規格（RS額定濃度的50%）。如果在配制與標示規格相比為150%的局部產品時觀察到活性成分析出，則可能需要使用不同的策略，這可以在ANDA前產品開發會議期間或通過受控通信在提交ANDA之前與機構討論。應報告較高和較低規格配方的組成和制備程序，盡管這些配方制劑不是在符合GMP條件下制備。IVRT方法的區分力應從以下三個概念來描述：靈敏度、特異性和選擇性。

IVRT Sensitivity IVRT   靈敏度

IVRT sensitivity is the ability to detect changes in the release rate, as a function of drug concentration in the formulation. If the IVRT method consistently identifies higher or lower rates of release for test formulations with increased or decreased drug concentrations, respectively, relative to the formulation at the nominal strength of the RS run in parallel on the same day, the IVRT method would generally be considered sensitive.

IVRT靈敏度是檢測釋放速率變化的能力，釋放速率作為制劑中藥物濃度的函數。如果同一天，對RS、較高規格和較低規格平行實驗，IVRT方法一致地識別制劑的釋放速率更高或更低，則通常認為IVRT方法是靈敏的。

IVRT Specificity IVRT  特異性

IVRT specificity is the ability to accurately monitor the proportionality of changes in the release rate as a function of drug concentration in the formulation. This proportionality may be illustrated in a plot of the relationship between the formulation concentration and the average IVRT release rate (slope). The specificity of the IVRT method should be calculated, plotted with a linear trendline, and the linearity quantified and reported as an r2 value. To be considered suitably specific, an IVRT method should be proportionally linear in its response to differences in release rates, with a minimum r2 value ≥ 0.95 for the correlation of the formulation concentration to the average IVRT release rate (slope).

IVRT特異性是準確監測釋放速率隨制劑中藥物濃度變化的比例的能力。該比例可以用制劑濃度和平均IVRT釋放速率（斜率）之間的關系圖來說明。應通過繪制線性趨勢線，將線性量化并報告為r2值，評估IVRT方法的特異性，。IVRT方法在其對釋放速率差異的響應中應該是成比例的線性的，制劑濃度與平均IVRT釋放速率（斜率）最小的r2值≥ 0.95，表示改方法具有合適的特異性。

IVRT specificity is a function of the proportionality of release rates across different strengths of the product, some, or all of which may be formulated as small-scale laboratory batches, with each strength having a slightly different formulation composition to accommodate for the different amount of the active ingredient in that strength of the product. These slight formulation differences across the different strengths of the product may impact the ideal proportionality of release rates across the different strengths of the product.

IVRT特異性是產品不同規格的釋放速率比例的函數，其中一些或全部可作為小規模實驗室批次配制，每個規格的制劑組成略有不同，以適應該產品規格中活性成分的不同量。產品不同規格的這些輕微配方差異可能會影響產品不同規格釋放速率的理想比例。

Thus, the proportional linearity of release rates across different strengths of the product may be impacted by formulation differences across the strengths that are independent of the proportional responsiveness of the IVRT method. The minimum r2 value ≥ 0.95 for the correlation of the formulation concentration to the average IVRT release rate (slope) takes into account that the IVRT method’s response to differences in release rates may not appear to be perfectly proportional because of formulation differences that are independent of the IVRT method.

因此，產品不同規格的釋放速率的比例線性可能受到不同規格的配方差異的影響，這些差異與IVRT方法的比例響應性無關。由于制劑差異與IVRT方法無關，考慮到IVRT方法對釋放速率差異的響應可能不全部成比例，因此，制劑濃度與平均IVRT釋放速率（斜率）的相關性最小r2值≥ 0.95的。

Note that the linearity of release rates across different strengths of the product (which assesses the specificity of the IVRT method, with a minimum r2 value ≥ 0.95) is fundamentally different and has different scientific considerations than the linearity of the release rate for a single strength of the product across the range of the sampling times (which assesses the IVRT method’s ability to monitor the steady state release kinetics of the active ingredient, with a minimum r2 value ≥ 0.97). Despite the potential for different scientific considerations to impact the linearity of the IVRT results in each context, for well-developed and suitably controlled IVRT methods, the r2 value ≥ 0.99 is routinely observed in both contexts.

注意，產品不同規格的釋放速率的線性（評估IVRT方法的特異性，最小r2值≥ 0.95）與在取樣時間范圍內的產品單一濃度的釋放速率的線性（這評估了IVRT方法監測活性成分穩態釋放動力學的能力，具有最小r2值≥0.97）。盡管在每種情況下，不同的科學考慮因素可能會影響IVRT結果的線性，但對于良好開發和適當控制的IVRT方法，在兩種情況下，r2值≥ 0.99通常都是滿足的。（如下圖r2=0.9915）

IVRT Selectivity IVRT   選擇性

IVRT selectivity is the ability of the IVRT method to discriminate the drug release rates between the reference topical product and the altered (50% and 150% nominal strength) concentration test formulations such that their release rates are determined to be statistically inequivalent compared to that from the nominal reference strength formulation. Determination of inequivalence between release rates should be evaluated using the statistical approach described in USP General Chapter<1724>.

IVRT選擇性是IVRT方法區分參考外用制劑和改變的（50%和150%標示規格）濃度測試制劑之間的藥物釋放速率的能力，從而確定它們的釋放速率與標示參考規格制劑的釋放速率在統計上不相等。應使用USP通用章節<1724>中描述的統計方法評估釋放速率之間的不等效性。

Specifically, the release rates from six cells dosed with the nominal reference strength formulation should be compared with the release rates from 6 cells dosed with the formulation at 150% the nominal reference strength, using the statistical approach described in USP General Chapter<1724>. All 12 cells being compared should have been run in parallel on the same day, and the release rate from the formulation at 150% the nominal reference strength should fail to show equivalence to the release rate from the nominal reference strength formulation.

具體而言，應使用USP通用<1724>章節中所述的統計方法，將六杯標示規格制劑的測試池的釋放率與六杯150%標示制劑的測試池釋放率進行比較，根據<1724>章節要求，這12杯應在同一天平行實驗，在標示規格的150%時，制劑的釋放速率不能顯示出與標示規格制劑的釋放率相等。

The release rates from 6 cells dosed with the nominal reference strength formulation should also be compared with the release rates from 6 cells dosed with the formulation at 50% the nominal reference strength, using the statistical approach described in USP General Chapter<1724>. All 12 cells being compared should have been run in parallel on the same day, and the release rate from the formulation at 50% the nominal reference strength should fail to show equivalence to the release rate from the nominal reference strength formulation.

還應使用USP通用章節<1724>中描述的統計方法，將6個測試池的標示規格濃度制劑（即100%規格）的釋放率與6個測試池50%規格時的釋放率進行比較，這12杯應在同一天平行實驗，50%規格制劑配方的釋放速率應與對照制劑的釋放率不等效。

IVRT Supplemental Selectivity IVRT  補充選擇性

IVRT supplemental selectivity is the ability of the IVRT method to discriminate the drug release rates between the reference topical product and an altered formulation with the same nominal reference strength, such that their release rates are determined to be statistically inequivalent.

IVRT補充選擇性是IVRT方法區分參考外用制劑和具有相同標示規格的改變制劑之間的藥物釋放速率的能力，從而確定它們的釋放速率在統計上不等效。

The demonstration of IVRT selectivity (distinct from supplemental selectivity) validates the ability of the IVRT method to discriminate differences in release rates under conditions when the release rate is expected to differ in a predictable manner (i.e., when there are different concentrations of drug in the formulation).

IVRT選擇性的證明（不同于補充選擇性）驗證了IVRT方法在預計釋放速率可以預測的方式不同的條件下（即，當制劑中存在不同濃度的藥物時）區分釋放速率差異的能力。

A separate and supplemental demonstration of the selectivity of an IVRT method, when feasible, independently validates the ability of the IVRT method to discriminate differences in release rates under the conditions of the pivotal IVRT study, in which the test and reference topical products are compared at the same strength. Thus, the supplemental demonstration of the selectivity of the IVRT method validates that it can detect differences in the release rate that are associated with aspects of the formulation other than the strength, and this is ideal, when feasible.

在可行的情況下，IVRT方法選擇性的單獨和補充證明獨立驗證了IVRT方法在關鍵IVRT研究條件下區分釋放率差異的能力，其中自制和對照外用制劑以相同的規格進行比較。因此，在可行情況下，理想情況下的IVRT方法選擇性的補充論證證明了它可以檢測與制劑的規格以外的方面相關的釋放速率的差異。

Determination of inequivalence between release rates should be evaluated using the statistical approach described in USP General Chapter<1724>. Specifically, the release rates from 6 cells dosed with the nominal reference strength formulation should be compared with the release rates from 6 cells dosed with an altered formulation, also at the nominal reference strength, using the statistical approach described in USP General Chapter<1724>. All 12 cells being compared should have been run in parallel on the same day, and the release rate from the altered formulation at the same nominal reference strength should fail to show equivalence to the release rate from the nominal reference strength formulation.

應使用USP通用章節<1724>中所述的統計方法評估釋放速率之間的不等效。具體而言，應使用USP通用章節<1724>中描述的統計方法，將對照標示配方給藥的6個測試池的釋放速率與相同規格下的改變配方給藥6個測試池的釋放率進行比較，并且在相同的標示規格下，來自改變的制劑的釋放速率應當顯示出與對照標示制劑的釋放率等效。

The altered formulation used in the assessment of supplemental selectivity should have the same nominal strength as the reference topical product, and may include changes in inactive ingredients, changes in inactive ingredient concentration(s), changes in the manufacturing processes, or combinations thereof. However, not all variations in a formulation will necessarily produce a difference in the release rate compared to the reference formulation, and if two similar formulations are found to have equivalent release rates, the demonstration of supplemental selectivity may be inconclusive.Therefore, applicants are encouraged to develop or select an altered formulation for the demonstration of supplemental selectivity based on differences in physicochemical and structural properties of the formulation (relative to the reference formulation) that are likely to alter the release rate of the active ingredient from the formulation. The altered formulation may be a marketed topical product, such as a different dosage form at the same strength of the same drug (e.g., a 5% gel versus a 5% ointment). Product batch information for all topical product lots used in IVRT method development, and validation studies, as applicable, should be submitted in the study reports. The topical product information should include, but not be limited to, information about the batch formula, manufacturing date, batch size, altered manufacturing processes (if applicable) and, if available, potency and content uniformity.

用于評估補充選擇性的改變配方應具有與對照外用制劑具有相同規格、不同配方的制劑，并且可改變的特性包括：非活性成分的變化、非活性成分濃度的變化、制造工藝的變化或其組合。然而，與對照配方制劑相比，并非所有制劑的變化都必然會產生釋放速率的差異，如果發現兩種類似的制劑具有相同的釋放速率，則不適用于論證補充選擇性。因此，鼓勵申請人根據制劑（相對于對照配方）的物理化學和結構性質的差異，開發或選擇一種可能會改變活性成分釋放速率的制劑，以論證補充選擇性。變更的制劑可以是上市的外用制劑，例如相同規格的相同藥物的不同劑型（例如，5%凝膠與5%軟膏）。如適用，應在研究報告中提交，IVRT方法開發和驗證研究中使用的所有外用制劑相關批次信息。包括但不限于:有關批次配方、生產日期、批次大小、變更的生產工藝（如適用）以及效價和含量均勻度（如可用）的信息。

J. Robustness   耐用性

The IVRT method may be considered robust to a variation in the test method if the average slope of an IVRT run under the altered IVRT method parametersis within ± 15% of the average slope of the precision and reproducibility IVRT runs. Robustness testing may encompass variations in the IVRT method that are relevant to the equipment and test method, for example:

如果在改變的IVRT方法參數下，IVRT運行的平均斜率在精密度和重現性研究中獲得IVRT運行平均斜率的±15%以內，則IVRT方法可被認為對該參數的的改變具有耐用性。耐用性測試可能包括IVRT方法中相關的設備和測試方法的改變，例如：

lTemperature variations (e.g., - 1°C and +1°C relative to 32°C ± 1°C) 溫度變化（例如，相對于32°C±1°C，-1°C和+1°C）

lDose volume variations (e.g., +10% and -10% in the dose volume) 上樣體積變化（例如，上樣體積的+10%和-10%）

lReceptor solution variations (e.g., slight change in composition and/or pH) 接受液變化（例如，輕微改變組成和/或pH值）

lMixing rate variation (e.g., slight change in stirring speed, as applicable) 混合速率變化（例如，輕微改變攪拌速率，如適用）

V. SAMPLE  ANALYTICAL  METHOD  VALIDATION  樣品分析方法驗證

While exploratory studies performed during IVRT method development may use an unvalidated sample analytical method, it is essential that all studies conducted as part of the IVRT method validation use a validated sample analytical method. A validated IVRT method should use a validated receptor solution sample analytical method. Therefore, a discussion of the sample analytical method for the IVRT method is included in this guidance under this section.

盡管IVRT方法開發期間進行的探索性研究,可以使用未經驗證的樣品分析方法，但作為IVRT方法驗證的一部分，在進行IVRT的所有研究都必須使用經驗證的樣品分析方法。已驗證的IVRT方法應使用已驗證的接受液樣品分析方法。因此，本部分討論的IVRT方法樣品分析方法。

It is important to note that the study protocols and reports related to the IVRT method are distinct from those for the sample analytical method that is used to quantify drug concentrations in IVRT receptor solution samples. The validation of a sample analytical method, in and of itself, does not demonstrate the validity of an IVRT method. Separate and specific reports should be submitted for the validation of the sample analysis (e.g., HPLC or UPLC) method and for the validation of the IVRT method.

值得注意的是，與IVRT方法相關的研究方案和報告與用于定量IVRT接受液樣品中藥物濃度的樣品分析方法不同。樣品分析方法的驗證本身并不能證明IVRT方法的有效性。因此，應提交單獨和具體的報告，已驗證樣品分析（如HPLC或UPLC）方法和IVRT方法的驗證報告。

Any results from studies of the IVRT method that are performed (during method development) using a different sample analytical method than that which is ultimately validated, cannot support a demonstration of the validity of the IVRT method. Information should be provided in the IVRT method validation report referencing the (separate) sample analytical method validation, and clearly indicate that all relevant results in the IVRT method validation report were obtained using a validated sample analytical method (as opposed to an analytical method with different parameters than those which were validated).

在方法開發期間使用的樣品分析方法與最終驗證的樣品分析方法不同，與其相關的IVRT方法研究結果無法支持IVRT方法的有效性。IVRT方法驗證報告中應提供參考（單獨）樣品分析方法驗證的信息，并明確指出IVRT方法確認報告中的所有相關結果均是使用經驗證的樣品分析方法獲得的（而不是使用與經驗證的分析方法具有不同參數的樣品分析方法）。

The receptor sample analysis procedures, typically involving HPLC or UPLC, should be performed using chromatography software (e.g., a chromatography data system) with audit trails, and should include a multi-point (6–8 concentration) calibration curve with suitable quality control samples, and should be validated in a manner compatible with the FDA guidance for industry Bioanalytical Method Validation (May 2018).

接受液中樣品分析方法，通常涉及HPLC或UPLC，應使用帶有審計跟蹤的色譜軟件（例如色譜數據系統）進行，，并應包括多點（6-8濃度）校準曲線，以及適當的質量控制樣品，并且應以符合FDA工業生物分析方法驗證指南（2018年5月）的方式進行驗證。

The validation of the receptor sample analytical method should include relevant qualifications of dilution integrity, if applicable, as well as stability assessments with the highest relevant temperature in the receptor solution for the longest relevant duration; the highest relevant temperature may be warmer than the IVRT membrane surface temperature because the temperature of the receptor solution is often higher than the temperature at the surface of the membrane (e.g., the temperature of the receptor solution may be 34°C when the temperature of membrane surface is 32°C, so stability assessments with the IVRT receptor solution may be performed at 34°C for 6 hours; the temperature would be higher for an IVRT with a vaginal gel, for example).

如適用，接受液中樣品分析方法的驗證應包括稀釋完整性的相關確認，以及在最長相關時間內接受液中最高相關溫度的穩定性評估；最高相關溫度可以略高于IVRT膜表面溫度，因為接受液的溫度通常高于膜表面的溫度（例如，當膜表面的溫度為32°C時，接受液的溫度可能為34°C，因此IVRT接受液的穩定性評估可在34°C下進行6小時；而在陰道凝膠制劑的IVRT研究中的溫度會更高）。

VI. IVRT PIVOTAL STUDY IVRT  正式研究

The IVRT pivotal study comparing the drug release rates between the test and reference topical products should be performed in a manner compatible with the general procedures and statistical analysis method specified in USP General Chapter<1724>. The cumulative amount of drug released at each sampling time point should be reported for each diffusion cell. Relevant summary statistics for the IVRT study should also be reported.

IVRT正式研究中應對自制制劑和對照外用制劑之間的藥物釋放率進行比較，應符合USP一般章節<1724>中規定的一般程序和統計分析方法進行。應報告每個擴散池在每個取樣時間點釋放的藥物累積量。還應報告IVRT研究的相關匯總統計數據。

A. Handling and Retention of Samples   樣品的處理和保存

Refer to 21 CFR 320.38, 320.63 and the guidances for industry Handling and Retention of BA and BE Testing Samples (May 2004) and Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c) (August 2020), as applicable, regarding considerations for retention of study drug samples and to 21 CFR 320.36 for requirements for maintenance of records of BE testing. Retention samples should be randomly selected from the drug supplies received before dispensing during the IVRT study in which the test topical product and RS are compared. Experimental observations that may have the potential to influence the interpretation of the study results, as well as any protocol deviations, should be reported

B.參考21 CFR 320.38、320.63以及FDA行業指南《生物利用度（BA）和生物等效性（BE）研究中測試樣品的處理和保存》（2004年5月）和《21 CFR 320.38(c) BE樣品留存的數量及生物利用度》（2020年8月），如適用，關于保留研究藥物樣品的考慮以及21 CFR 320.36關于保存BE檢測記錄的要求。在IVRT中比較自研外用制劑和RS前應從收到的藥品中隨機選擇樣品進行留樣。應報告可能影響研究結果解釋的實驗觀察結果以及任何方案偏差。Control of Study Procedures 研究程序的控制

Procedures   研究程序的控制

Study procedures that have the potential to influence the results of the study should be appropriately controlled. Also, experimental observations that may have the potential to influence the interpretation of the study results, as well as any protocol or standard operating procedure (SOP) deviations, should be reported.

應適當控制可能影響研究結果的研究程序。此外，應報告可能影響研究結果解釋的實驗觀察結果，以及任何方案或標準操作程序（SOP）偏差。

In addition, investigators should perform the IVRT validation and pivotal studies within a quality management system that includes, but is not limited to, documented procedures for:

此外，研究人員應在質量管理體系內進行IVRT驗證和正式研究，該體系包括但不限于：

lStudy personnel identification, training, qualification, and responsibilities研究人員識別、培訓、資質和職責

lStudy management and study management personnel responsibilities研究管理和研究管理人員職責

lQuality control (QC) and QC personnel responsibilities質量控制（QC）和QC人員職責

lQuality assurance (QA) and QA personnel responsibilities質量保證（QA）和QA人員職責

lUse of SOPs SOP的使用

lUse of study protocols研究方案的使用

lUse of study reports研究報告的使用

lMaintenance and control of the study facility environment and systems研究設施環境和系統的維護和控制

lQualification and calibration of instruments and computerized systems儀器和計算機系統的驗證和校準

lGood documentation practices including, but not limited to, contemporaneous documentation of study procedures and recording of experimental observations or deviations from procedures specified in the study protocol or in relevant SOPs良好的文件記錄規范，包括但不限于：研究程序的同期記錄和實驗觀察結果的記錄，或與研究方案或相關SOP中規定的程序的偏差

lMaintenance of suitable records that facilitate the reconstruction of study events and procedures, including study sample handling and storage records (e.g., sample tracking logs), audit trails for sample analysis procedures, control of study materials and reagents, and electronic data control對記錄進行適當維護，有助于重現研究過程，包括：研究樣品處理和保存記錄（例如，樣品跟蹤日志）、樣品分析過程的審計跟蹤、研究物料和試劑的控制以及電子數據控制

lArchival of study records研究記錄歸檔

C.Blinding Procedure   盲法程序

A detailed description of the blinding procedure should be provided in the study protocol and final report for the IVRT pivotal study. The packaging of the test topical product and RS should be similar in appearance to maintain adequate blinding of the investigator and any experimental operators. Once blinded, the test topical product and RS should be identified by a random designation, e.g., “A" or “B."

IVRT正式研究的研究方案和最終報告中應詳細說明盲法程序。自制外用制劑和RS的包裝外觀應相似，以保持研究者和任何實驗操作人員的充分隨機。一旦采用盲法程序，應通過隨機名稱（例如“A"或“B"）來區別自制外用制劑和RS

D.Dosing   上樣

In the IVRT pivotal study, the test topical product and RS should be dosed in an alternating pattern on successive diffusion cells. There are two possible sequences for the alternating pattern (either ABABAB or BABABA). One of these two dosing sequences should be randomly selected.

在IVRT正式研究中，自制外用制劑和RS應在連續擴散池上交替給藥。交替模式有兩種可能的序列（ABABAB或BABABA）。可以隨機選擇這兩種給藥順序中的一種。

VII. SUBMITTING INFORMATION ON IVRT STUDIES IN AN ANDA  ANDA中遞交的IVRT研究信息

For IVRT studies with topical products submitted in ANDAs that are intended to support a demonstration of BE, detailed study protocols, relevant SOPs, and detailed reports should be submitted for the IVRT method validation and the IVRT pivotal study. In addition, a detailed report describing the IVRT method development should be submitted. These protocols, SOPs, and reports should be submitted in module 5.3.1.2 of the electronic Common Technical Document (eCTD) and should describe experimental procedures, study controls, quality management procedures, and data analyses.

對于在ANDA中提交的外用制劑用于支持BE論證的IVRT研究，應為IVRT方法驗證和IVRT正式研究提交詳細的研究方案、相關SOPs和詳細報告。此外，還應提交一份詳細報告，關于IVRT方法的開發。這些方案、SOPs和報告應在電子通用技術文件（eCTD）的模塊5.3.1.2中提交，并應描述實驗程序、研究控制、質量管理程序和數據分析。

Note that the study protocols, SOPs, and reports related to the IVRT method are distinct from those for the sample analytical method that is used to quantify drug concentrations in IVRT receptor solution samples (e.g., a HPLC or UPLC method). Separate protocols and SOPs should be submitted for the sample analytical method validation. Sample analytical method development and validation reports, pivotal IVRT study sample analysis reports, as well as associated SOPs and protocols relevant to the sample analysis for an IVRT study should be submitted in Module 5.3.1.4 of the eCTD.

注意:與IVRT方法相關的研究方案、SOPs和報告與用于定量IVRT接受液中樣品藥物濃度的樣品分析方法（例如HPLC或UPLC方法）不同。樣品分析方法驗證應提交單獨的方案和SOPs。樣品分析方法開發和驗證報告、正式IVRT研究樣品分析報告以及與IVRT研究的樣品分析相關的相關SOPs和協議,應在eCTD的模塊5.3.1.4中提交。